Mechanisms of Disease: Methyl-binding domain proteins as potential therapeutic targets in cancer

Nature Clinical Practice Oncology

Volumn 4, Issue 5, 2007, Pages 305-315

  Sansom, Owen J ^a   Maddison, Kathryn ^b   Clarke, Alan R ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BLEOMYCIN; CISPLATIN; DEOXYRIBONUCLEOPROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 1; METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 3; METHYL CPG BINDING PROTEIN 4; PROTEIN KAISO; PROTEIN MLH1; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN;

CANCER; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 19; COLORECTAL CANCER; CPG ISLAND; DNA BINDING; DNA DAMAGE; DNA METHYLATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENOMIC INSTABILITY; HUMAN; MISMATCH REPAIR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETT SYNDROME; REVIEW; TRANSCRIPTION REGULATION; CELL TRANSFORMATION; DRUG EFFECT; GENETIC EPIGENESIS; NEOPLASM; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 34247860920     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0812     Document Type: Review

References (91)

1. Ballestar E and Wolffe AP (2001) Methyl-CpG-binding proteins: Targeting specific gene repression. Eur J Biochem 268: 1-6
2. Svedruzic ZM and Reich NO (2004) The mechanism of target base attack in DNA cytosine carbon 5 methylation. Biochemistry 43: 11460-11473
3. Urnov FD and Wolffe AP (2001) Chromatin remodeling and transcriptional activation: The cast (in order of appearance). Oncogene 20: 2991-3006
4. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428
5. Hendrich B and Tweedie S (2003) The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 19 269-277
6. Jones PA and Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 293: 1068-1070
7. Strathdee G et al. (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341
8. Plumb JA et al. (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044
9. Eads CA et al. (2002) Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic mice. Cancer Res 62: 1296-1269
10. Lin H et al. (2006) Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol 26: 2976-2983
11. Kantarjian HM and Issa JP (2005) Decitabine dosing schedules. Semin Hematol 42 (Suppl 2): S17-S22
12. Kantarjian H et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106: 1794-1803
13. Li E et al. (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926
14. Jackson-Grusby L et al. (2001) Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 27: 31-39
15. Kim M et al. (2004) Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Res 32: 5742-5749
16. Gaudet F et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492
17. Yamada Y et al. (2005) Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102 13580-13585
18. Meehan RR et al. (1989) Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58 499-507
19. Lewis JD et al. (1992) Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69: 905-914
20. Ng HH et al. (1999) MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23: 58-61
21. Cross SH et al. (1997) A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 16: 256-259
22. Feng Q et al. (2002) Identification and functional characterization of the p66/p68 components of the MeCP1 complex. Mol Cell Biol 22: 536-546
23. Feng Q and Zhang Y (2001) The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 15: 827-832
24. Hendrich B and Bird A (1998) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538-6547
25. Hendrich B et al. (1999) Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome 10: 906-912
26. Prokhortchouk A et al. (2001) The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev 15: 1613-1618
27. Nan X et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389
28. Jones PL et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191
29. Wade PA et al. (1999) Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 23 62-66
30. Zhang Y et al. (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13: 1924-1935
31. Hendrich B et al. (1999) The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401 301-304
32. Kondo E et al. (2005) The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes. Mol Cell Biol 25: 4388-4396
33. Fraga MF et al. (2003) The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 31: 1765-1774
34. Saito M and Ishikawa F (2002) The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem 277: 35434-35439
35. Ballestar E et al. (2003) Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22: 6335-6345
36. Lopez-Serra L et al. (2006) A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG Islands of tumor suppressor genes in human cancer. Cancer Res 66: 8342-8346
37. Fujita N et al. (1999) Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol Cell Biol 19: 6415-6426
38. Villa R et al. (2006) The methyl-CpG binding protein MBD1 is required for PML-RARα function. Proc Natl Acad Sci USA 103: 1400-1405
39. Watanabe S et al. (2003) Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin. Proc Natl Acad Sci USA 100: 12859-12864
40. Bader S et al. (2003) MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene 22: 3506-3510
41. Zhao X et al. (2003) Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci USA 100: 6777-6782
42. Lewis JD et al. (1992) Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69: 905-914
43. Feng and Zhang (2001) The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 15: 827-832
44. Feng Q et al. (2002) Identification and functional characterization of the p66/p68 components of the MeCP1 complex. Mol Cell Biol 22: 536-546
45. Sekimata M et al. (2001) Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2. J Biol Chem 276: 42632-42638
46. Hendrich B et al. (2001) Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev 15: 710-723
47. Sansom OJ et al. (2003) Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 34: 145-147
48. Suzuki H et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422
49. Magdinier F and Wolffe AP (2001) Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 98: 4990-4995
50. Trinh BN et al. (2002) DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol 22: 2906-2917
51. Sansom OJ et al. (2005) MBD2 deficiency does not accelerate p53 mediated lymphomagenesis. Oncogene 24: 2430-2432
52. Campbell PM et al. (2004) Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 25: 499-507
53. Ivanov MA et al. (2003) Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. Gene Med 5: 893-899
54. Zhang Y et al. (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13: 1924-1935
55. Zhu Y et al. (2004) Genetic and epigenetic analyses of MBD3 in colon and lung cancer. Br J Cancer 90: 1972-1975
56. Noh EJ et al. (2005) Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells. Cancer Res 65: 11400-11410
57. Jiang CL et al. (2002) MBD3L1 and MBD3L2, two new proteins homologous to the methyl-CpG-binding proteins MBD2 and MBD3: characterization of MBD3L1 as a testis-specific transcriptional repressor. Genomics 80: 621-629
58. Jin SG et al. (2005) MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing. J Biol Chem 280: 12700-12709
59. Prokhortchouk A (2006) Kaiso-deficient mice show resistance to intestinal cancer. Mol Cell Biol 26: 199-208
60. Prokhortchouk A et al. (2001) The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev 15: 1613-1618
61. Daniel JM and Reynolds AB (1999) The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol 19: 3614-3623
62. Ruzov A et al. (2004) Kaiso is a genome-wide repressor of transcription that is essential for amphibian development. Development 131: 6185-6194
63. Kim SW et al. (2004) Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nat Cell Biol 6: 1212-1220
64. van Roy FM and McCrea PD (2005) A role for Kaiso-p120ctn complexes in cancer? Nat Rev Cancer 5: 956-964
65. Daniel JM et al. (2002) The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG inucleotides. Nucleic Acids Res 30 2911-2919
66. Rodova M et al. (2004) Regulation of the rapsyn promoter by kaiso and delta-catenin. Mol Cell Biol 24: 7188-7196
67. Park JI et al. (2005) Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Dev Cell 8: 843-854
68. Filion GJ et al. (2006) A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell Biol 26: 169-181
69. Geerdink N et al. (2002) MECP2 mutation in a boy with severe neonatal encephalopathy: Clinical, neuropathological and molecular findings. Neuropediatrics 33: 33-36
70. Villard L et al. (2000) Two affected boys in a Rett syndrome family: Clinical and molecular findings. Neurology 55: 1188-1193
71. Nan X et al. (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481
72. Nan X et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389
73. Klose RJ et al. (2005) DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19: 667-678
74. Bernard D et al. (2006) The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth. Oncogene 25: 1358-1366
75. Muller HM et al. (2003) MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer 89: 1934-1939
76. Nakagawachi T et al. (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22: 8835-8844
77. Bellacosa A (2001) Role of MED1 (MBD4) gene in DNA repair and human cancer. J Cell Physiol 187: 137-144
78. Kouidou S et al. (2006) Methylation and repeats in silent and nonsense mutations of p53. Mutat Res 599: 167-177
79. Millar CB et al. (2002) Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297: 403-405
80. Wong E et al. (2002) Mbd4 inactivation increases C-T transition mutations and promotes gastrointestinal tumor formation. Proc Natl Acad Sci USA 99: 14937-14942
81. Fritzell JA et al. (1997) Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res 57: 5143-5147
82. Toft NJ et al. (1999) Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci USA 96: 3911-3915
83. Meyers M et al. (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61: 5193-5201
84. Sansom OJ et al. (2003) MBD4 deficiency reduces the apoptotic response to DNA damaging agents in the murine small intestine. Oncogene 22: 7130-7136
85. Cortellino S et al. (2003) The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 100 15071-15076
86. Parsons BL et al. (2003) MED1: A central molecule for maintenance of genome integrity and response to DNA damage. Proc Natl Acad Sci USA 100: 14601-14602
87. Sansom OJ et al. (2004) MBD4 deficiency does not increase mutation or accelerate tumourigenesis in mice lacking MMR. Oncogene 23 5693-5696
88. Screaton RA et al. (2003) Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: A potential link between genome surveillance and apoptosis. Proc Natl Acad Sci USA 100: 5211-5216
89. Bader S et al. (1999) Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. Oncogene 18: 8044-8047
90. Wade PA (2001) Methyl CpG-binding proteins and transcriptional repression. Bioessays 23: 1131-1137
91. Le Guezennec X et al. (2006) MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol 26: 843-851